Formulation development supported by light scattering techniques
contributed by Malvern Panalytical |
Researchers develop methods to test protein stability under a variety of conditions.
Researchers from Novozymes Biopharma and Malvern Instruments have been collaborating using light scattering techniques to demonstrate the short- and long-term stability of the novel recombinant human albumins Albucult and Recombumin.
These rAlbumins have been developed and optimised to deliver a safe, stable and regulatorycompliant product for therapeutic formulations.
The teams applied the resolving and detection capabilities of size exclusion chromatography light scattering (SEC-LS) and dynamic light scattering (DLS) offered by Malvern systems to monitor the stability of these Novozymes products.
The work is described in an article ‘Tools for evaluating the stability of human recombinant albumins used in human therapeutics’. See: www.malvern.com/formulationdevelopment
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.